Details for New Drug Application (NDA): 203630
✉ Email this page to a colleague
The generic ingredient in IRBESARTAN AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; irbesartan. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; irbesartan profile page.
Summary for 203630
| Tradename: | IRBESARTAN AND HYDROCHLOROTHIAZIDE |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | hydrochlorothiazide; irbesartan |
| Patents: | 0 |
Pharmacology for NDA: 203630
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
Suppliers and Packaging for NDA: 203630
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 203630 | ANDA | Aurobindo Pharma Limited | 65862-629 | 65862-629-05 | 500 TABLET, FILM COATED in 1 BOTTLE (65862-629-05) |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 203630 | ANDA | Aurobindo Pharma Limited | 65862-629 | 65862-629-30 | 30 TABLET, FILM COATED in 1 BOTTLE (65862-629-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG;150MG | ||||
| Approval Date: | Feb 22, 2013 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG;300MG | ||||
| Approval Date: | Feb 22, 2013 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG;300MG | ||||
| Approval Date: | Mar 31, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
